Author:
Lautz Zoë,Kautz-Freimuth Sibylle,Shukri Arim,Redaèlli Marcus,Rhiem Kerstin,Schmutzler Rita,Stock Stephanie
Funder
Landeszentrum Gesundheit Nordrhein-Westfalen (LZG.NRW) Gesundheitscampus Süd 9
Reference55 articles.
1. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 Mutation Carriers;Kuchenbaecker;JAMA,2017
2. Howlader N., Noone A., Krapcho M., Miller D., Brest A., Yu M., et al. EER Cancer Statistics Review, 1975–2017, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020. 2020.
3. Robert Koch-Institut. https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/krebsarten_node.html. [Accessed 16.06.2023] 2021.
4. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study;Rhiem;Breast Cancer Res,2012
5. High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer;Bick;Breast Cancer Res Treat,2019